×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MIST – milestone pharmaceuticals inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MIST
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
08:00 am
mist
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/28
07:29 am
mist
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/27
08:33 am
mist
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
Low
Report
Milestone Pharmaceuticals announces U.S. availability of cardamyst [Yahoo! Finance]
1/26
08:18 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
Medium
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) [Yahoo! Finance]
1/26
08:00 am
mist
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
Low
Report
Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)
1/15
09:56 am
mist
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
Low
Report
Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense [Seeking Alpha]
1/7
08:51 am
mist
Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]
Medium
Report
Milestone announces acceptance of MAA by EMA for etripamil nasal spray [Yahoo! Finance]
1/6
12:50 pm
mist
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Low
Report
Milestone Pharmaceuticals (NASDAQ:MIST) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2025
07:01 am
mist
milestone pharmaceuticals inc. - common shares
BEAT
Report
0.0%
milestone pharmaceuticals inc. - common shares
8/12/2025
07:05 am
mist
milestone pharmaceuticals inc. - common shares
MISS
Report
0.7%
milestone pharmaceuticals inc. - common shares
5/14/2025
07:04 am
mist
milestone pharmaceuticals inc. - common shares
MISS
Report
-0.8%
milestone pharmaceuticals inc. - common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/5
04:31 pm
mist
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Bharucha David
Low
Report
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Bharucha David
2/5
04:30 pm
mist
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Hasija Amit
Low
Report
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Hasija Amit
2/5
04:30 pm
mist
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Muller Lorenz
Low
Report
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Muller Lorenz
2/5
04:30 pm
mist
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Oliveto Joseph
Low
Report
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Oliveto Joseph
2/5
04:30 pm
mist
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Nelson Jeffrey Edward
Low
Report
Form 4/A Milestone Pharmaceutical For: Feb 02 Filed by: Nelson Jeffrey Edward
2/4
05:52 pm
mist
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Muller Lorenz
Medium
Report
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Muller Lorenz
2/4
05:51 pm
mist
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Hasija Amit
Medium
Report
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Hasija Amit
2/4
05:50 pm
mist
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Nelson Jeffrey Edward
Medium
Report
Form 4 Milestone Pharmaceutical For: Feb 02 Filed by: Nelson Jeffrey Edward
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/3
Form SC 13G/A Milestone Pharmaceutical Filed by: Venrock Healthcare Capital Partners II, L.P.
19.2%
5/9 Form 4 Milestone Pharmaceutical For: May 09 Filed by: RTW INVESTMENTS, LP 17.1%
3/6 Q4/2019 12/31/2019 EPS -0.750 ZacksConsensus -0.520 ActVsEst (0.230) - Miss 11.6%
1/2 Form 4 Milestone Pharmaceutical For: Dec 30 Filed by: WONG RODERICK 10.4%
3/24 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. 8.3%
5/24 Form 8-K Milestone Pharmaceutical For: May 24 7.8%
7/8 Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha] 7.8%
2/5 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock. 5.9%
5/21 Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting 5.7%
1/13 Form 4 Milestone Pharmaceutical For: Jan 13 Filed by: RTW INVESTMENTS, LP 5.6%
5/9 Form 4 Milestone Pharmaceutical For: May 09 Filed by: RTW INVESTMENTS, LP 17.1%
3/6 Q4/2019 12/31/2019 EPS -0.750 ZacksConsensus -0.520 ActVsEst (0.230) - Miss 11.6%
1/2 Form 4 Milestone Pharmaceutical For: Dec 30 Filed by: WONG RODERICK 10.4%
3/24 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. 8.3%
5/24 Form 8-K Milestone Pharmaceutical For: May 24 7.8%
7/8 Milestone Pharmaceuticals: Interesting, But Not Well-Differentiated From Generic Competition [Seeking Alpha] 7.8%
2/5 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) had its "buy" rating re-affirmed by analysts at Piper Sandler. They now have a $26.50 price target on the stock. 5.9%
5/21 Milestone Pharmaceuticals Presents Studies on the Economic Impacts of PSVT at the ISPOR 2019 Annual Meeting 5.7%
1/13 Form 4 Milestone Pharmaceutical For: Jan 13 Filed by: RTW INVESTMENTS, LP 5.6%
TOP News Decliners
3/23
Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
-87.1%
3/12 Form SC 13D/A Milestone Pharmaceutical Filed by: Novo Holdings A/S -8.4%
3/19 Form 4 Milestone Pharmaceutical For: Mar 02 Filed by: RTW INVESTMENTS, LP -7.3%
6/7 Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow [Seeking Alpha] -6.1%
11/8 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.9%
5/15 Form 8-K Milestone Pharmaceutical For: May 13 -3.9%
3/6 Form S-8 Milestone Pharmaceutical -3.8%
6/3 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is now covered by analysts at Cowen Inc. They set a "buy" rating and a $32.00 price target on the stock. -3.3%
11/14 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences -2.9%
10/3 Form 4 Milestone Pharmaceutical For: Oct 01 Filed by: RTW INVESTMENTS, LP -2.8%
3/12 Form SC 13D/A Milestone Pharmaceutical Filed by: Novo Holdings A/S -8.4%
3/19 Form 4 Milestone Pharmaceutical For: Mar 02 Filed by: RTW INVESTMENTS, LP -7.3%
6/7 Milestone Pharmaceuticals (MIST) Presents At 2019 Jefferies Global Healthcare Conference - Slideshow [Seeking Alpha] -6.1%
11/8 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.9%
5/15 Form 8-K Milestone Pharmaceutical For: May 13 -3.9%
3/6 Form S-8 Milestone Pharmaceutical -3.8%
6/3 Milestone Pharmaceuticals Inc. (NASDAQ: MIST) is now covered by analysts at Cowen Inc. They set a "buy" rating and a $32.00 price target on the stock. -3.3%
11/14 Milestone Pharmaceuticals to Present at Upcoming Investor Conferences -2.9%
10/3 Form 4 Milestone Pharmaceutical For: Oct 01 Filed by: RTW INVESTMENTS, LP -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: